CellCentric secures $120 million in Series C funding to advance inobrodib, a promising oral treatment for multiple myeloma.

Target Overview

CellCentric is a clinical-stage biotechnology company based in Naarden, The Netherlands, specializing in innovative cancer therapies. The focus of the company is on developing inobrodib, a first-in-class oral p300/CBP inhibitor aimed at treating multiple myeloma, a form of blood cancer. On May 19, 2025, CellCentric announced the successful completion of a $120 million Series C funding round, which will facilitate the late-stage development of inobrodib.

The drug has shown promise in clinical trials, highlighting a significant need for new treatment options in a landscape where many patients do not respond to existing therapies. Inobrodib's distinctive mechanism of action and oral delivery system position it as a potentially transformative treatment for patients battling multiple myeloma.

Industry Overview

Multiple myeloma remains one of the challenging areas in oncology, primarily affecting older adults. While advancements in treatment have been made, including the introduction of newer therapies, the unmet medical need in this pa